New growth in the hepatitis market will be driven by the increasing patient potential for hepatitis C and the development of combination therapy. This is due to chronic infections transmitted before blood transfusions were screened for the virus progressing to severe liver disease and the lack of efficacy of current therapy. Novel laboratory and animal models will uncover new targets for vaccine discovery efforts. Drugs of Tomorrow 2001: Hepatitis provides an in-depth analysis of hepatitis pipeline products and forecasts their performance to 2008. The report provides comprehensive coverage of all phase II and phase III treatments indicated for the prophylaxis and treatment of hepatitis B and hepatitis C. Also, the current and future commercial attractiveness of these drugs is assessed.
